342415-52-5Relevant academic research and scientific papers
Visible-Light-Photocatalyzed Reductions of N-Heterocyclic Nitroaryls to Anilines Utilizing Ascorbic Acid Reductant
Todorov, Aleksandar R.,Aikonen, Santeri,Muuronen, Mikko,Helaja, Juho
, p. 3764 - 3768 (2019)
A photoreductive protocol utilizing [Ru(bpy)3]2+ photocatalyst, blue light LEDs, and ascorbic acid (AscH2) has been developed to reduce nitro N-heteroaryls to the corresponding anilines. Based on experimental and computational results and previous studies, we propose that the reaction proceeds via proton-coupled electron transfer between AscH2, photocatalyst, and the nitro N-heteroaryl. The method offers a green catalytic procedure to reduce, e.g., 4-/8-nitroquinolines to the corresponding aminoquinolines, substructures present in important antimalarial drugs.
Synthesis and evaluation of a large library of nitroxoline derivatives as pancreatic cancer antiproliferative agents
Brocco, Davide,Cama, Alessandro,Carradori, Simone,De Lellis, Laura,Florio, Rosalba,Guglielmi, Paolo,Secci, Daniela,Sobolev, Anatoly P.,Spano, Mattia,Veschi, Serena
, p. 1331 - 1344 (2020/07/10)
Pancreatic cancer (PC) is one of the deadliest carcinomas and in most cases, which are diagnosed with locally advanced or metastatic disease, current therapeutic options are highly unsatisfactory. Based on the anti-proliferative effects shown by nitroxoline, an old urinary antibacterial agent, we explored a large library of newly synthesised derivatives to unravel the importance of the OH moiety and pyridine ring of the parent compound. The new derivatives showed a valuable anti-proliferative effect and some displayed a greater effect as compared to nitroxoline against three pancreatic cancer cell lines with different genetic profiles. In particular, in silico pharmacokinetic data, clonogenicity assays and selectivity indexes of the most promising compounds showed several advantages for such derivatives, as compared to nitroxoline. Moreover, some of these novel compounds had stronger effects on cell viability and/or clonogenic capacity in PC cells as compared to erlotinib, a targeted agent approved for PC treatment.
Copper(ii)-mediated base pairing involving the artificial nucleobase 3: H -imidazo[4,5- f] quinolin-5-ol
Sandmann, Nikolas,Bachmann, Jim,Hepp, Alexander,Doltsinis, Nikos L.,Müller, Jens
, p. 10505 - 10515 (2019/07/22)
Different N3-substituted derivatives of the new ligand 3H-imidazo[4,5-f]quinolin-5-ol were synthesized. The three pKa values of its nucleoside derivative 1 were determined as 2.72 ± 0.09, 5.2 ± 0.2 and 9.7 ± 0.2. Sophisticated computational met
1,2-NAPHTHOQUINONE DERIVATIVE AND METHOD FOR PREPARING SAME
-
Paragraph 0150, (2016/11/21)
Disclosed are a compound represented by Formula (1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1to R6, X1 to X4, and n are the same as defined in Claim 1.
1,2-Naphthoquinone-based Derivatives and and Methods for Preparing them
-
Paragraph 0528-0532, (2016/11/24)
The present invention relates to a compound represented by chemical formula (1), a pharmaceutically acceptable salt, a hydrate, a solvate, a prodrug, a tautomer, an enantiomer, or a pharmaceutically acceptable diastereomer thereof, a preparing method thereof, and a medical composition having a treating or preventing effect of metabolic diseases containing the same. Here, R_1 to R_3, and X_1 to X_6 are the same as defined in a first claim.COPYRIGHT KIPO 2015
Synthesis and anticonvulsant activity evaluation of 8-alkoxy-5-(4H-1,2,4- triazol-4-yl)quinoline derivatives
Wang, Shi-Ben,Deng, Xian-Qing,Zheng, Yan,Zhang, Hong-Jian,Quan, Zhe-Shan
, p. 32 - 40 (2013/03/28)
Two series of 8-alkoxy-5-(4H-1,2,4-triazol-4-yl)quinolines and 8-alkoxy-5-(2H-1,2,4-triazol-3-one-4-yl)quinolines were synthesized. The anticonvulsant activity of these compounds was evaluated with maximal electroshock seizure test and rotarod test. Among the synthesized compounds, 8-octoxy-5-(4H-1,2,4-triazol-4-yl)quinoline (4g) was the most active compound with ED50 of 8.80 mg/kg, TD50 of 176.03 mg/kg and protective index of 20.0. Its neurotoxicity was lower than all other synthesized compounds and also markedly lower than that of the reference drug carbamazepine. In addition, the potency of compound 4g against seizures induced by pentylenetetrazole, 3-mercaptopropionic acid, and bicuculline suggested its broad spectrum activity, and the mechanisms of action including inhibition of voltage-gated ion channels and modulation of GABAergic activity might involve in its anticonvulsant activity.
A new metallostar complex based on an aluminum(iii) 8-hydroxyquinoline core as a potential bimodal contrast agent
Debroye, Elke,Dehaen, Geert,Eliseeva, Svetlana V.,Laurent, Sophie,Vander Elst, Luce,Muller, Robert N.,Binnemans, Koen,Parac-Vogt, Tatjana N.
, p. 10549 - 10556 (2013/01/14)
A ditopic DTPA monoamide derivative containing an 8-hydroxyquinoline moiety was synthesized and the corresponding gadolinium(iii) complex ([Gd(H5)(H 2O)]-) was prepared. After adding aluminum(iii), the 8-hydroxyquinoline part self-as
